N/A N=20 Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics
Specific Phobia
Primary: Snake Questionnaire (SNAQ) — 9.6; 9.7 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,439 Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery
Surgery · Blood Loss
Primary: Unanticipated Bleeding — 0; 100; 0 percentage of participants
N/A N=30 Procellera and Negative Pressure Therapy for Acute Wounds
Wound
Primary: Wound Infection — 13; 12 participants
N/A N=38 Evaluation of Videoconferencing Versus Telephone Genetic Counseling
Remote Consultation, Teleconsultation · Remote Consultation, Video
Primary: Assessment of Knowledge Retention of Genetic Counseling Information Via 8-Question Pre- and Post-Counseling Assessment — 5.63; 4.37; 6.50; 4.74 Number of correct answers…
Phase 4 N=18 The Effects of General Anesthetics on Upper Airway Collapsibility in Healthy Subjects
Airway Complication of Anaesthesia · Healthy
Primary: Upper Airway Closing Pressure — -9.83; -10.77 cm H20
Phase 3 N=37 Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)
Von Willebrand Disease
Primary: Percentage of Participants With Treatment Success for Treated Bleeding Episodes — 100.0 Percent of participants
N/A N=9 An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
Rheumatoid Arthritis
Primary: Mean Change From Baseline in Disease-activity Score 28-Erythrocyte Sedimentation Rate at Month 24 — -2.31 Scores on a scale — p=0.0078
N/A N=402 Regional Data Exchange to Improve Medication Safety
Drug Toxicity
Primary: Transition Drug Risk — 6.4; 5.8 units: risk-weighted discrepancies — p=0.175
Phase 3 N=150 Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age
Hypertension · Chronic Kidney Disease
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at End Point (Week 78 or Last Observation Carried Forward (LOCF) — -13.3; -15.5 millimeter(s) of…
Phase 3 N=31 A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications
Advanced Parkinson's Disease
Primary: Average Daily Normalized "Off" Time: Change From Baseline To The Final PEG-J Visit — 7.37; 2.72 hours — p=<0.001
N/A N=43 Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist
Myopia
Primary: Comfort (Subjective Assessment) — 9.12; 9.16 units on a scale
Phase 2 N=63 Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
HIV Infections · Cachexia · Anorexia
Primary: Change in Body Weight — 5.4; 3.5; 7.0; 3.5 kg
Phase 4 N=90 Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade
Readiness to Discharge
Primary: The Primary Outcome is Time Until a Patient is "Ready for Discharge." — 3.2; 3.2 days
N/A N=98 An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis
Anemia
Primary: Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 2 (Month 1) — 23 participants
Phase 2 N=22 Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
Age Related Macular Degeneration · Choroidal Neovascularization · Macular Edema
Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants